Elise Gray-Gaillard

PhD candidate @JHUBME | M.S. Immunology and Oncology @unil | Whitaker Fellow 2018 @Ludwig_Cancer Lausanne | Class of 2017 @UVABME

[Elise Gray-Gaillard @EGrayGaillard]

Excited to share the work from my master thesis in Switzerland with @IrvingMelita!

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Preclinical model for evaluating human TCRs against chimeric syngeneic tumors https://t.co/ynEOqdRnTo @EGrayGaillard @IrvingMelita

[Warren Grayson @GraysonLab]

See some of our latest research driven by Dallas Altamirano in @Adv_Biology!

[Elise Gray-Gaillard @EGrayGaillard]

Super cool review by my genius best friend @GarrettBeeghly. Proud of you 🎉

[Garrett Beeghly, PhD @GarrettBeeghly]

Excited that our review in @AnnualReviews BME is now out with @kumarlabucb! Here, we describe how shared physical motifs mediate invasion of molecularly diverse solid tumors, using breast and brain cancer as examples https://t.co/8hzGGm4tUu

[Elise Gray-Gaillard @EGrayGaillard]

@AHorenberg Congrats again 🎉🎉❤️

[Elise Gray-Gaillard @EGrayGaillard]

Excited to share the work Aaron Lopacinski and I started during our 4th year Capstone project @UVABME and @AndrewSweatt1 pushed to the finish in @janeslab modeling the kinetics of CVB3 infection!

[Janes Lab @janeslab]

Happy to share our most recent @biorxivpreprint modeling CVB3 kinetics. Great work @AndrewSweatt1 and Aaron Lopacinski!

https://t.co/GPNH5dIGYr

[Elise Gray-Gaillard @EGrayGaillard]

Thrilled to announce I will be joining @JHUBME’s PhD program this fall, working with @JHElisseeff and @dpardol1 !! See you in the fall, Baltimore! 👩🏻‍🔬

[Elise Gray-Gaillard @EGrayGaillard]

Reminiscing about days in the lab while #stayingathome and so thankful for this research experience during my Whitaker Fellowship @IIEglobal @Ludwig_Cancer

[Ludwig Cancer @Ludwig_Cancer]

Study led by Ludwig Lausanne and @EPFL_en researchers devises & tests in mice a new CAR-T cell therapy that can be switched on & off on demand to control runaway immune responses—a common & potentially deadly side effect of the cancer #immunotherapy. https://t.co/UfbM69jWzh

[Naveed Tavakol, PhD @naveedtavakol]

Exciting work coming from my friend and former #whitaker Lausanne buddy Elise Gray-Gaillard (#twitterless 🙄), who stayed in Switzerland to finish up this study! #CART #Immunotherapy